Literature DB >> 2937473

B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro.

K A Paganelli, S S Evans, T Han, H Ozer.   

Abstract

Malignant B cells from hairy cell leukemia (HCL) patients are unable to proliferate when stimulated with standard B cell mitogens. Using chromatographically purified B cell growth factor (BCGF), HCL can be stimulated to proliferate as assessed by incorporation of tritiated thymidine [3HTdR] into DNA. Proliferation was found to be time dependent, with no detectable 3H-TdR incorporation in up to three days of culture, and significant stimulation evident at days 6 and 10. The presence of 10% BCGF in culture was an absolute requirement for HCL proliferation; however, this BCGF-induced DNA synthesis could be further augmented by the addition of anti-immunoglobulin heavy chain antibodies. BCGF-induced proliferation was abrogated in six of six patients by addition of 1,000 U/mL of recombinant alpha 2-interferon (IFN) at day 0, although 1,000 U/mL of recombinant gamma-IFN had no inhibitory effect in five of six patients studied. Specific cellular receptors for type I IFN were demonstrated in HCL by inhibition of binding of 125I-alpha 2-IFN by a 40-fold excess of unlabeled alpha 2 or beta IFN with no inhibition by unlabeled gamma-IFN. These data demonstrate that malignant HCL lymphoblasts express specific type I IFN receptors and that type I, but not type II IFN, can inhibit growth factor-induced DNA synthesis by hairy cells in vitro. They further suggest a direct antiproliferative mechanism of action for IFN in HCL and predict equivalent clinical activity by either alpha or beta, but not gamma IFN in this malignancy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937473

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Interferons regulate the in vitro differentiation of multilineage lympho-myeloid stem cells in hairy cell leukemia.

Authors:  R Michalevicz; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

Review 2.  The biology of interferon actions.

Authors:  G Gastl; C Huber
Journal:  Blut       Date:  1988-05

3.  Response of neoplasms of B cell lineage to the proliferative effects of B cell growth factor and the phorbol ester TPA.

Authors:  M C Kinney; R D Collins; J Whitlock; J B Cousar; L B Vogler
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

4.  Modulation of the response to B-cell growth factor (BCGF) of hairy cells from a patient under IFN-alpha therapy.

Authors:  E Génot; C Mathiot; J P Kolb
Journal:  Blut       Date:  1987-07

5.  Hairy-cells are not lysed by NK-cells.

Authors:  F Sigaux; F Chapuis; S Castaigne; L Degos; G Flandrin; J C Gluckman
Journal:  Blut       Date:  1987-05

6.  [Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia].

Authors:  N Niederle; C Doberauer; O Kloke; K Höffken; C G Schmidt
Journal:  Klin Wochenschr       Date:  1987-07-15

7.  Biochemical and immunological responses of hairy cell leukemia patients to interferon beta.

Authors:  A M Liberati; M Horisberger; M Schippa; F Di Clemente; M Fizzotti; S Filippo; M G Proietti; S Arzano; P Berruto; L Palmisano
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders.

Authors:  H E Heslop; A C Bianchi; F T Cordingley; M Turner; W Chandima; C P De Mel; A V Hoffbrand; M K Brenner
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

10.  Inhibition of mitogen stimulated growth of human colon cancer cells by interferon.

Authors:  A W Hamburger; M E Condon; K O'Donnell
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.